Research Plan for Early Disease Screening Biomarkers in Healthy Individuals
ConditionHealth
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorZhonghao Fang
About this trial
The establishment of reference intervals for biomarkers in healthy populations relies on large-scale, standardized cohort data. However, current baseline data for hematology, liver and kidney function, and multi-omics (genomics, transcriptomics, proteomics, and metabolomics) in Chinese healthy populations are constrained by significant regional disparities and insufficient sample sizes, limiting the development of early disease screening markers. To address these challenges, this study aims to: (1) establish a comprehensive database for hematology and liver/kidney function indicators; (2) construct a multi-omics database using blood and sputum samples; and (3) explore the correlations among multi-omics indicators and their associations with demographic characteristics.
Eligibility criteria
Qualifiers
Age: 18 - 65 years old, gender not restricted;
No clear history of chronic diseases (hypertension, diabetes, cardiovascular and cerebrovascular diseases, chronic liver and kidney diseases, tumors, etc.);
No infection history in the past 3 months (fever, cough, sore throat, etc.);
No use of antibiotics, hormones, immunosuppressants, etc. within the past 1 month;
Disqualifiers
Abnormal laboratory indicators (ALT/AST > 2 times the upper limit of normal value, Cr > upper limit of normal value, main indicators of blood routine test are abnormal and have clinical significance);
Pregnant or lactating women;
Recent (within 3 months) history of surgery, trauma or blood transfusion;
Mental illness or cognitive impairment that makes it impossible to cooperate with the research.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
300 Participants
are grouped into 1 trial groupSponsors and collaborators
Zhonghao Fang
Lead sponsor
Guangzhou Medical University
Sponsor institution
Fifth Affiliated Hospital of Guangzhou Medical University
Collaborator
Source ClinicalTrials.gov